Held by 5 specialist biotech funds
High ConvergenceNo credit card required
“# Signal Note: Driehaus Capital Initiates $86M Position in Scholar Rock Driehaus's $86M entry into SRRK signals conviction in the company's lead program, SRK-181 (a myostatin inhibitor for spinal muscular atrophy), which is progressing through late-stage development with potential catalysts including Phase 2b data and regulatory interactions over the next 12-18 months.”
AI analyst context — unlock full analysis
# Signal Note: Driehaus Capital Initiates $86M Position in Scholar Rock Driehaus's $86M entry into SRRK signals conviction in the company's lead program, SRK-181 (a myostatin inhibitor for spinal muscular atrophy), which is progressing through late-stage development with potential catalysts including Phase 2b data and regulatory interactions over the next 12-18 months. The position size (~1.95M shares) represents meaningful capital commitment from a growth-focused manager, suggesting confidence in clinical outcomes or commercial potential despite current market conditions. This follows broader institutional appetite for neuromuscular disease therapeutics, though execution risk remains elevated pending efficacy readouts.
# Signal Note: Redmile Initiates $230M Position in SRRK Redmile Group's $230M entry into Scholar Rock signals conviction in the biotech's lead program, SRK-181, a myostatin inhibitor in Phase 2 for spinal muscular atrophy (SMA) and other neuromuscular indications. The timing suggests positioning ahead of near-term data readouts, likely including Phase 2 SMA interim or top-line results expected in 2024-2025. Given Redmile's track record in clinical-stage healthcare bets, this represents meaningful institutional validation but carries execution risk tied to efficacy and safety outcomes in a competitive muscle-wasting space.
Rock Springs Capital's $32.3M initiating position in SRRK signals conviction in Scholar Rock's clinical pipeline, likely driven by upcoming catalysts for SRK-181 (activin A inhibitor for muscle diseases) or momentum in their TGF-beta program. The healthcare-focused, concentrated fund structure suggests conviction in near-term catalysts or valuation asymmetry; timing should be monitored against expected Phase 2/3 readouts in their core indications (SMA, Duchenne muscular dystrophy).
**Signal Note: Casdin Capital Entry into SRRK** Casdin's $11.5M position in Scholar Rock likely reflects confidence in SRK-181, the company's lead myostatin inhibitor for spinal muscular atrophy (SMA), which reported positive Phase 2 data in 2023 and is advancing toward pivotal trials. The timing suggests anticipation of near-term clinical or partnering catalysts, particularly as the SMA market remains underpenetrated despite existing therapies and the myostatin pathway offers potential for combination approaches.
# Signal Note: Eventide Initiates $107M SRRK Position Eventide's substantial new position in Scholar Rock signals conviction in SRK-015, the company's myostatin inhibitor for spinal muscular atrophy (SMA), which has shown potential to address progressive weakness in SMA Type 2/3 patients beyond current standard-of-care. The timing aligns with expected Phase 2 data readout and potential regulatory pathway clarification, making this a bet on both clinical validation and valuation expansion in the rare disease space. This contrasts with Eventide's typical ultra-selective biotech allocation, suggesting they view SRRK's mechanism and unmet need justification as compelling.